PEPIDH1M vaccine + vorasidenib Clinical Trials

1 actively recruiting trial across 1 location

Filter by location:

Durham, North Carolina1 trial

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Duke University Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.